Peptide questions · Survodutide
How long does survodutide take to work?
Reviewed Evidence: EstablishedPublished by PepVault
Survodutide’s onset is days–2 weeks, its peak effect comes at 76 weeks (trial endpoint), and its typical duration is ongoing, by the library’s timeline (backed by clinical trial data).
The timeline’s basis: Phase 2 RCT (le Roux 2024); phase 3 SYNCHRONIZE-1 and -2 (NEJM 2026) and SYNCHRONIZE-MASLD (Nat Med 2026). Not approved.
Survodutide week by week
The library places five of its research notes on survodutide on the days they cover, from day 1 to day 336 and on: 5 on randomized trials.
Day 1 is the first day of a run. Each bar is one of the library’s research notes, placed on the days it covers.
| When | The note | Evidence |
|---|---|---|
| Days 1–14 (weeks 1–2) | The 0.3 mg start | Randomized trial |
| Days 15–168 (weeks 3–24) | The slow climb | Randomized trial |
| From day 99 on | 3.6 mg, the lower phase 3 dose | Randomized trial |
| From day 141 on | 6.0 mg, the top phase 3 dose | Randomized trial |
| Days 169–336 (weeks 25–48) | Liver fat: where the glucagon arm shows | Randomized trial |

Model. Individual results vary.
The survodutide timeline’s milestones
The library’s timeline for survodutide marks 6 points from week 1 to week 76, backed by clinical trial data overall.
- Week 1: Commonly reported: appetite dipping in the first days on 0.3 mg
- Week 3: Phase 2 stepped to 0.6 mg here; the phase 3 trials climb more slowly
- Week 8: Commonly reported: nausea or vomiting after step-ups, easing once a dose holds
- Week 24: Phase 3 trials reach their maintenance dose, 3.6 or 6.0 mg, around here
- Week 48: Where its liver trial measured liver fat on MRI
- Week 76: Where the SYNCHRONIZE weight trials read out
The weeks are the library’s reference timeline from studies and reported use, not a promise of what any one person will notice.
Why survodutide takes that long
The library states no half-life with a number for survodutide (it says: “Long enough for once-weekly dosing: a fatty-acid chain binds it to albumin; phase I measured it in people (Jungnik 2023), but the figure is not in the trial summaries”), so this page can’t work out a build-up; the timing rests on the notes above.
The notes on survodutide follow the trials’ dose steps, 0.3mg, 3.6mg and 6mg, so the later weeks also describe higher steps than the first ones; these are steps from studies, not a schedule for a person.
Survodutide against other metabolic & GLP-1 compounds
The library holds an onset-and-peak timeline for 21 metabolic & GLP-1 compounds, survodutide among them; 15 of the others share its onset of days–2 weeks.
| Compound | Onset | Peak effect |
|---|---|---|
| Semaglutide | Days–2 weeks | 60–68 weeks |
| Tirzepatide | Days–2 weeks | 72+ weeks |
| Retatrutide | Days–2 weeks | 48+ weeks |
| Dulaglutide | Days–2 weeks | 24–52 weeks (glucose) |
| Exenatide | First dose (after-meal glucose) | 24–30 weeks (HbA1c) |
| Setmelanotide | 1–2 weeks (hunger) | 52 weeks (BMI) |
| Orforglipron | Days–2 weeks | 72 weeks (trial endpoint) |
| Survodutide | Days–2 weeks | 76 weeks (trial endpoint) |
| Mazdutide | Days–2 weeks | 48–60 weeks |
| Pemvidutide | Days–2 weeks | 48+ weeks |
| Cagrilintide | Days–2 weeks | 26–68 weeks (trial endpoints) |
| Pramlintide | First meal (fullness, after-meal glucose) | 16–52 weeks (weight, HbA1c) |
| CagriSema | Days–2 weeks | 68+ weeks |
| Eloralintide | Days–2 weeks | 48 weeks (phase 2 endpoint) |
| Petrelintide | Days–2 weeks | 42 weeks (phase 2, still falling) |
| Amycretin | Days–2 weeks | 36 weeks (longest trial so far) |
| VK2735 | Days–2 weeks | 78 weeks (phase 3 endpoint, not yet read out) |
| Enicepatide | Days–2 weeks | 48 weeks (phase 2 endpoint, no plateau) |
| Ecnoglutide | Days–2 weeks | 48 weeks (phase 3, no plateau) |
| Efinopegdutide | Weeks | 24–52 weeks (trial endpoints) |
| SLU-PP-332 | Unknown in people | Unknown in people |
Questions people ask
How long does survodutide take to work?
Survodutide’s onset is days–2 weeks, its peak effect comes at 76 weeks (trial endpoint), and its typical duration is ongoing, by the library’s timeline (backed by clinical trial data).
When does survodutide reach its peak effect?
By the library’s timeline, survodutide’s peak effect comes at 76 weeks (trial endpoint), backed by clinical trial data.
How long is survodutide usually run?
The library’s timeline gives survodutide’s typical duration as ongoing; its cycle note says: Phase 3 trials run it continuously for 76 weeks after a slow climb of about 24 weeks.
What does the library say about the first days on survodutide?
Its first note on survodutide, for days 1–14 (weeks 1–2), is “The 0.3 mg start”, resting on randomized trials.